XSHE
300980
Market cap448mUSD
Oct 09, Last price
15.97CNY
1D
0.19%
1Q
-26.88%
IPO
-28.86%
Name
Hubei Xiangyuan New Material Technology Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hubei Xiangyuan New Material Technology Inc. is a Chinese firm that specializes in the innovation, manufacturing, and distribution of advanced foam materials, particularly cross-linked polyolefin and silicone-based foams. The company offers a comprehensive range of products, including various types of polyethylene foams such as irradiation cross-linked and chemical crosslinked variants, alongside radiation-cross-linked, semirigid, and closed-cell long sheet foams. Their portfolio also features 520 polyolefin foam, polyurethane foam, HFPP foam, and silicone foam, among other specialized items. These versatile materials find extensive application across numerous industries. They are integral to automotive interiors, sports and leisure equipment, protective packaging and cushioning, medical devices, and air-conditioning systems. Furthermore, their uses extend to construction materials, electronic components, toys, pipe insulation (including anti-condensation solutions), diverse industrial applications, consumer products, and healthcare goods. Established in 2003, Hubei Xiangyuan New Material Technology Inc. maintains its headquarters in Hanchuan, China.
Key people
Zhixiang Wei
Chairman of the Board · since 2015
Pan Wang
Chief Financial Officer, Secretary of the Board · since 2019
Qiong Wei
General Manager, Director · since 2015
Yonghong Huang
Deputy General Manager, Director, Chief Purchasing Officer · since 2021
Zhenghua Song
Deputy General Manager · since 2019
Shiming Wang
Deputy General Manager · since 2019
Jianping Duan
Deputy General Manager, Director · since 2019
Youfang Jiang
Sales Director, Director · since 2021
Ling Yang
Production Director, Director · since 2024
Independent Director · since 2025
Aiping Lu
Independent Director · since 2019
Ling Su
Independent Director · since 2019
Zhengjia Wang
Independent Director · since 2019
Tao Xiong
Independent Director · since 2025
Kaitang Zhou
Independent Director · since 2025
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||